Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. Issue 3 (8th March 2017)

• Record Type: Journal Article
• Authors: Arroyo, Rafael; Sempere, Angel P; Ruiz-Beato, Elena; Prefasi, Daniel; Carreño, Agata; Roset, Montse; Maurino, Jorge
• Is Part Of: BMJ open. Volume 7:Issue 3(2017)
• Publication Date: 2017-03-08
• Subjects: patient preferences -- disease-modifying therapies -- rating-based experiment -- conjoint analysis; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2016-014433
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS). Design: A cross-sectional observational study. Setting: The data reported were from 17 MS units throughout Spain. Participants: Adult patients with relapsing-remitting MS. Main outcome: A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration. Results: Patients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT. Conclusions: Patient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk–benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.